Valent P - Search Results

1

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.

Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C, Bruno S, Pagano L, Criscuolo M, Zanotti R, Bonifacio M, Tosi P, Arock M, Valent P, Cavo M, Soverini S. Mancini M, et al. Among authors: valent p. Biomark Res. 2023 Mar 10;11(1):29. doi: 10.1186/s40364-023-00468-7. Biomark Res. 2023. PMID: 36894973 Free PMC article.

2

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Féger F, et al. Among authors: valent p. Int Arch Allergy Immunol. 2002 Feb;127(2):110-4. doi: 10.1159/000048179. Int Arch Allergy Immunol. 2002. PMID: 11919418 Review.

3

Signal transduction-associated and cell activation-linked antigens expressed in human mast cells.

Valent P, Ghannadan M, Hauswirth AW, Schernthaner GH, Sperr WR, Arock M. Valent P, et al. Int J Hematol. 2002 May;75(4):357-62. doi: 10.1007/BF02982124. Int J Hematol. 2002. PMID: 12041664 Review.

4

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.

Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD. Valent P, et al. Leuk Res. 2003 Jul;27(7):635-41. doi: 10.1016/s0145-2126(02)00168-6. Leuk Res. 2003. PMID: 12681363 Review.

5

Diagnosis and treatment of systemic mastocytosis: state of the art.

Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD. Valent P, et al. Br J Haematol. 2003 Sep;122(5):695-717. doi: 10.1046/j.1365-2141.2003.04575.x. Br J Haematol. 2003. PMID: 12930381 Free article. Review. No abstract available.

6

On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.

Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M, Sperr WR, Arock M, Samorapoompichit P, Horny HP, Metcalfe DD. Valent P, et al. Eur J Clin Invest. 2004 Aug;34 Suppl 2:41-52. doi: 10.1111/j.0960-135X.2004.01369.x. Eur J Clin Invest. 2004. PMID: 15291805 Review.

7

Mastocytosis: pathology, genetics, and current options for therapy.

Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Valent P, et al. Leuk Lymphoma. 2005 Jan;46(1):35-48. doi: 10.1080/10428190400010775. Leuk Lymphoma. 2005. PMID: 15621779 Review.

8

The European Competence Network on Mastocytosis (ECNM).

Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, Födinger M, Grabbe J, Hartmann K, Henz BM, Horny HP, Kluin-Nelemans HC, Lima M, Marone G, Orfao A, Parwaresch RM, Sillaber C, Sotlar K, Sperr WR, Triggiani M, Van Doormaal JJ, Wolff K, Zuberbier T. Valent P, et al. Wien Klin Wochenschr. 2004 Oct 30;116(19-20):647-51. doi: 10.1007/s00508-004-0253-3. Wien Klin Wochenschr. 2004. PMID: 15941072

9

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.

Arock M, Valent P. Arock M, et al. Among authors: valent p. Expert Rev Hematol. 2010 Aug;3(4):497-516. doi: 10.1586/ehm.10.42. Expert Rev Hematol. 2010. PMID: 21083038 Review.

10

Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria.

Valent P, Horny HP, Triggiani M, Arock M. Valent P, et al. Int Arch Allergy Immunol. 2011;156(2):119-27. doi: 10.1159/000323763. Epub 2011 May 16. Int Arch Allergy Immunol. 2011. PMID: 21576982 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

942 results

Search Page